4.7 Article

PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Cell Biology

Myeloid Cells in Glioblastoma Microenvironment

Alessandra De Leo et al.

Summary: Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with a unique immune microenvironment that is resistant to immunotherapy. Myeloid cells play a crucial role in regulating immune and therapeutic responses in GBM. Studying the characteristics and functions of different populations of myeloid cells in GBM offers new insights for targeting specific cells for therapeutic purposes.
Article Neurosciences

Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs

Maria-Magdalena Georgescu et al.

Summary: The study conducted a comparative integrated analysis of the FGFR glioblastoma subgroup, revealing four novel clinically targetable FGFR2 and FGFR3 alterations associated with aggressive phenotype and canonical pathway feedback inhibition, highlighting important therapeutic implications.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)

Article Oncology

Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma

Claudia Alexandra Dumitru et al.

Summary: The study identified Tctex1 as an independent prognostic marker for overall survival in GBM patients, with high expression significantly associated with short overall survival and progression-free survival. Tctex1 promotes the aggressiveness and proliferation of GBM cells, indicating its potential as a therapeutic target in GBM.

CANCERS (2021)

Article Oncology

Bioinformatic analysis of PLOD family member expression and prognostic value in non-small cell lung cancer

Qi Qi et al.

Summary: This study demonstrated that PLODs are highly expressed in NSCLC tissues, with high expression being associated with poor prognosis in LUAD but not in LUSC. PLOD1 and PLOD3 were identified as independent risk factors for relapse-free survival and overall survival in LUAD, while genetic alterations of PLODs in LUSC patients were associated with favorable OS. Additionally, PLODs were significantly linked to tumor immunity in lung cancer.

TRANSLATIONAL CANCER RESEARCH (2021)

Article Oncology

High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas

Daolin Si et al.

CANCER MANAGEMENT AND RESEARCH (2020)

Review Oncology

Management of glioblastoma: State of the art and future directions

Aaron C. Tan et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Article Biochemistry & Molecular Biology

CD99 Expression in Glioblastoma Molecular Subtypes and Role in Migration and Invasion

Lais C. Cardoso et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Review Oncology

Glioblastoma: Microenvironment and Niche Concept

Davide Schiffer et al.

CANCERS (2019)

Review Oncology

Current state of immunotherapy for glioblastoma

Michael Lim et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Article Cell Biology

PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC

Hongzhi Du et al.

CELL DEATH & DISEASE (2017)

Article Biochemistry & Molecular Biology

Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium

Steven E. Reid et al.

EMBO JOURNAL (2017)

Review Medicine, Research & Experimental

PLOD2 in cancer research

Hongzhi Du et al.

BIOMEDICINE & PHARMACOTHERAPY (2017)

Article Biochemistry & Molecular Biology

Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space

Yulong Chen et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

Review Clinical Neurology

The role of CD44 in glioblastoma multiforme

Kelly L. Mooney et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2016)

Review Oncology

Hypoxia and the extracellular matrix: drivers of tumour metastasis

Daniele M. Gilkes et al.

NATURE REVIEWS CANCER (2014)

Article Oncology

Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis

T. S. Karin Eisinger-Mathason et al.

CANCER DISCOVERY (2013)

Article Gastroenterology & Hepatology

PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection

Takehiro Noda et al.

LIVER INTERNATIONAL (2012)

Review Oncology

A complete compilation of matrix metalloproteinase expression in human malignant gliomas

Carsten Hagemann et al.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2012)

Article Biochemistry & Molecular Biology

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

Kandice R. Levental et al.

Article Pharmacology & Pharmacy

Activation of KATP channels increases anticancer drug delivery to brain tumors and survival

Nagendra S. Ningaraj et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2009)

Article Cell Biology

An essential role for p120-catenin in Src- and Rac1-mediated anchorage-independent cell growth

Michael R. Dohn et al.

JOURNAL OF CELL BIOLOGY (2009)

Review Medicine, General & Internal

Malignant gliomas in adults

Patrick Y. Wen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Clinical Neurology

Histology-based expression profiling yields novel prognostic markers in human glioblastoma

SM Dong et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)

Article Biochemistry & Molecular Biology

Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis

AJ van der Slot et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Article Biochemistry & Molecular Biology

Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen

GA Di Lullo et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2002)